AJADUO 25/5 MG (Empagliflozin (25mg) + Linagliptin (5mg))

AJADUO 25/5 MG TAB is a prescribed pharmaceutical that comprises two active substances: Empagliflozin at a dose of 25 mg and Linagliptin at 5 mg. This particular combination is tailored for adult patients suffering from Type 2 Diabetes Mellitus, aimed at thoroughly managing elevated blood glucose levels. It serves as an addition to dietary measures and physical activity and is generally recommended when lower doses or alternative diabetes treatments fail to meet the necessary blood sugar levels. One of the key advantages of the Empagliflozin element in AJADUO is its proven efficacy in decreasing the likelihood of cardiovascular mortality, as well as hospital admissions related to heart failure and the progression of kidney disease in individuals with Type 2 Diabetes who also have existing heart or kidney issues. Thus, AJADUO 25/5 MG TAB proves to be an essential option for comprehensive diabetes care, particularly for individuals at elevated risk. The medication works through two different yet complementary mechanisms to enhance blood sugar regulation and provide additional benefits. The Empagliflozin component functions by inhibiting the SGLT2 protein in the kidneys, effectively reducing glucose absorption and promoting its excretion in urine, which results in lowered blood glucose levels. Linagliptin acts by blocking the DPP-4 enzyme, leading to increased levels of incretin hormones that stimulate insulin secretion and diminish glucose production from the liver. The cooperative effect of both components allows AJADUO to aggressively reduce blood sugar while also offering protective cardiovascular and kidney advantages, particularly vital for patients with Type 2 Diabetes facing these risks.